Publications by authors named "Manon De Graaf"
Purpose: To assess prognosis of ER-low expression and its dynamics in HER2- metastatic breast cancer (BC) and to compare sensitivity to nivolumab between ER-low and triple-negative (TN) BC.
Experimental Design: Two cohorts were analyzed: a multicenter cohort of 982 patients with HER2- metastatic BC, and one prospective cohort of 110 patients with ER<10%/HER2- metastatic BC enrolled in the TONIC trial (testing nivolumab). Endpoints were: overall survival (OS) and post-relapse survival (PRS) in the retrospective cohort; progression-free survival (PFS), OS, and clinical benefit rate (CBR) in the TONIC trial.
Immune checkpoint inhibition (ICI) has fundamentally changed cancer treatment. However, only a minority of patients with metastatic triple negative breast cancer (TNBC) benefit from ICI, and the determinants of response remain largely unknown. To better understand the factors influencing patient outcome, we assembled a longitudinal cohort with tissue from multiple timepoints, including primary tumor, pre-treatment metastatic tumor, and on-treatment metastatic tumor from 117 patients treated with ICI (nivolumab) in the phase II TONIC trial.
View Article and Find Full Text PDFArticle Synopsis
- Immune checkpoint inhibition (ICI) combined with chemotherapy is the standard treatment for stage II-III triple-negative breast cancer, but the effectiveness of ICI alone remains unclear.
- The adaptive BELLINI trial found that short-term ICI treatments led to immune activation in a significant portion of patients, correlating immune response with tumor-infiltrating lymphocytes.
- A new cohort is being studied with patients who have high levels of these lymphocytes; early results show a notable rate of major and complete pathological responses post-treatment, suggesting that neoadjuvant ICI could be a promising approach without chemotherapy.
T1 colorectal cancer patients' perspective on information provision and therapeutic decision-making after local resection.
United European Gastroenterol J
December 2024
Background: Decision-making after local resection of T1 colorectal cancer (T1CRC) is often complex and calls for optimal information provision as well as active patient involvement.
Objective: The aim was to evaluate the perceptions of patients with T1CRC on information provision and therapeutic decision-making.
Methods: This multicenter cross-sectional study included patients who underwent endoscopic or local surgical resection as initial treatment.
Endoglin and squamous cell carcinomas.
Front Med (Lausanne)
June 2023
Despite the fact that the role of endoglin on endothelial cells has been extensively described, its expression and biological role on (epithelial) cancer cells is still debatable. Especially its function on squamous cell carcinoma (SCC) cells is largely unknown. Therefore, we investigated SCC endoglin expression and function in three types of SCCs; head and neck (HNSCC), esophageal (ESCC) and vulvar (VSCC) cancers.
View Article and Find Full Text PDF